When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IPHA - Innate Pharma: Moving Into The Padcev Space
Innate Pharma S.A.
2025-03-21 09:10:35 ET
Summary
Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025.
Lacutamab, a key asset, received US FDA Breakthrough Therapy designation, enhancing its development prospects and partnership potential.
Financially, IPHA has a cash runway until the end of 2025, but may face a cash crunch, likely requiring equity raises or partnerships, in my opinion.
Despite risks, including potential dilution and high development costs, I remain optimistic and maintain a "Buy" rating for IPHA.